Cubist Systematic Strategies LLC Invests $2.81 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Cubist Systematic Strategies LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 119,065 shares of the company's stock, valued at approximately $2,805,000. Cubist Systematic Strategies LLC owned 0.12% of Dyne Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DYN. abrdn plc acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $608,000. Raymond James Financial Inc. bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth $2,340,000. Barclays PLC lifted its position in shares of Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after purchasing an additional 128,246 shares in the last quarter. Schroder Investment Management Group lifted its position in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after purchasing an additional 56,961 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Dyne Therapeutics by 54.5% in the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock worth $913,000 after purchasing an additional 13,677 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 6,237 shares of company stock valued at $77,760 over the last quarter. 14.14% of the stock is owned by company insiders.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded up $0.15 on Friday, hitting $11.89. The company's stock had a trading volume of 952,336 shares, compared to its average volume of 2,450,478. The stock's 50 day moving average is $10.37 and its 200-day moving average is $17.64. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a market capitalization of $1.35 billion, a PE ratio of -3.34 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. HC Wainwright cut their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Chardan Capital reissued a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 9th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target on the stock. Finally, Piper Sandler dropped their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $46.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.